Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections (Q37785979)

23 August 2017

title

Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections (English)

1 reference

23 August 2017

1 reference

Effie L. Kuti

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20822479

8 July 2024

Joseph L. Kuti

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20822479

8 July 2024

language of work or name

English

0 references

publication date

1 October 2010

1 reference

full work available at URL

23 August 2017

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7872289

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20822479

http://www.informapharmascience.com/doi/abs/10.1517/17425255.2010.518143

8 July 2024

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20822479

https://europepmc.org/articles/PMC7872289

8 July 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20822479

https://europepmc.org/articles/PMC7872289?pdf=render

8 July 2024

file format

Portable Document Format

online access status

open access

content deliverer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20822479

https://doi.org/10.1517/17425255.2010.518143

8 July 2024

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20822479

http://www.tandfonline.com/doi/pdf/10.1517/17425255.2010.518143

8 July 2024

1 reference

10.1517/17425255.2010.518143

DOI

https://api.crossref.org/works/10.1517/17425255.2010.518143

Expert Opinion on Drug Metabolism & Toxicology

8 July 2024

published in

1 reference

23 August 2017

volume

6

1 reference

23 August 2017

issue

10

1 reference

23 August 2017

page(s)

1287-1300

1 reference

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

The changing face of fungal infections in health care settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

The new generation of antifungal drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Comparison of echinocandin antifungals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Morphological changes of Candida albicans induced by micafungin (FK463), a water-soluble echinocandin-like lipopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Effects of micafungin on the morphology of Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Extended daily dialysis does not affect the pharmacokinetics of anidulafungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Pharmacology and antifungal properties of anidulafungin, a new echinocandin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Pharmacokinetics and tissue distribution of anidulafungin in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

CNS pharmacokinetics of antifungal agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Micafungin concentrations from brain tissue and pancreatic pseudocyst fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Serum differentially alters the antifungal properties of echinocandin drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Fungicidal activity of anidulafungin in serum from patients does not correlate to its susceptible breakpoint against Candida spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Resistance to echinocandin-class antifungal drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Attenuation of the activity of caspofungin at high concentrations against candida albicans: possible role of cell wall integrity and calcineurin pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

In vitro activities of various antifungal drugs against Aspergillus terreus: Global assessment using the methodology of the European committee on antimicrobial susceptibility testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Combination echinocandin-polyene treatment of murine mucormycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Pharmacodynamic implications for use of antifungal agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Anidulafungin in combination with amphotericin B against Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Anidulafungin versus fluconazole for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

The safety of anidulafungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Safety and pharmacokinetics of coadministered voriconazole and anidulafungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Lack of pharmacokinetic interaction between anidulafungin and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2010.518143

Cilofungin inhibition of (1-3)-beta-glucan synthase: the lipophilic side chain is essential for inhibition of enzyme activity

21 January 2018

1 reference

12 December 2020

Semisynthetic chemical modification of the antifungal lipopeptide echinocandin B (ECB): structure-activity studies of the lipophilic and geometric parameters of polyarylated acyl analogs of ECB

1 reference

12 December 2020

Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo

1 reference

12 December 2020

In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species

1 reference

12 December 2020

Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors.

1 reference

12 December 2020

Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis

1 reference

12 December 2020

Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts

1 reference

12 December 2020

Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits

1 reference

12 December 2020

Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment

1 reference

12 December 2020

Utilization and dosage pattern of echinocandins for treatment of fungal infections in US hospital practice

1 reference

12 December 2020

Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.

1 reference

12 December 2020

10.1517/17425255.2010.518143

Identifiers

DOI

1 reference

National Center for Biotechnology Information

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20822479

8 July 2024

1 reference